The masterfully engineered anti-VEGF1
- Beovu® contains more active binding agents per dose than other anti-VEGFs1
Maximizes
the amount of anti-VEGF in a
50μL volume due to its size1
12x more molecules
than aflibercept
at the same volume2*
Potent, high-affinity
binding
to VEGF-A isoforms1
VEGF-A=vascular endothelial cell growth factor-A; VEGFR-1=vascular endothelial growth factor receptor-1; VEGFR-2=vascular endothelial growth factor receptor-2.
*6 mg of Beovu® equals approximately 12 times the molecules per Injection as the 2 mg dose of aflibercept.2
Illustration not drawn to scale.
REFERENCES
-
Data on file. RTH258-C002 Clinical Study Report. Novartis; 2018.
-
Data on file. RTH258 Dose comparison of Beovu and aflibercept for nAMD. Novartis.
Beovu® SmPC
Rate this content:
11/20 GLOPH/BRO/0307
